Current Guidelines for Heart Failure Management
The 2022 ACC/AHA/HFSA guidelines establish four foundational medication classes (the "four pillars") that should be initiated simultaneously or sequentially in all patients with heart failure with reduced ejection fraction (HFrEF): angiotensin receptor-neprilysin inhibitors (ARNi) or ACE inhibitors/ARBs, evidence-based beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2i). 1
Core GDMT for HFrEF (Stages C and D)
The Four Pillars - Start Early and Together
The modern approach abandons the old sequential titration model. You can and should initiate all four medication classes simultaneously at low doses without waiting to reach target dosing of one before starting another 1. This represents a fundamental shift in practice:
- ARNi (preferred) or ACE inhibitor/ARB: ARNi (sacubitril/valsartan) is now preferred over ACE inhibitors as first-line therapy
- Evidence-based beta-blockers: Carvedilol, metoprolol succinate, or bisoprolol
- MRA: Spironolactone or eplerenone
- SGLT2i: Dapagliflozin or empagliflozin (Class 1A recommendation regardless of diabetes status)
Practical Implementation Strategy
Start all four medications at initial low doses recommended for HFrEF, then uptitrate each toward target doses as tolerated 1. The sequence can be guided by clinical factors—blood pressure, heart rate, renal function, potassium levels—but do not delay initiating the next medication while waiting to reach target dose of the previous one.
Additional Therapies Based on Specific Populations
For African American Patients with Persistent Symptoms
Add hydralazine-isosorbide dinitrate combination if patients remain symptomatic despite optimal use of the four pillars 1. This recommendation is based on the A-HeFT trial showing mortality reduction and is cost-effective at <$60,000 per life-year gained. The evidence specifically supports this in self-identified African American patients with HFrEF already on ACE inhibitor (or ARB), beta-blocker, and MRA.
Important caveat: There are insufficient data for concomitant use with ARNi, so this combination should be used cautiously in that setting 1.
For Patients Intolerant of First-Line Agents
If patients cannot tolerate ARNi, ACE inhibitors, or ARBs due to hypotension, renal insufficiency, or other drug intolerance, refer to a heart failure specialist for guidance 1. Hydralazine-isosorbide dinitrate might be considered in these situations, though the benefit in non-African American patients is uncertain and not demonstrated in recent observational data 1.
HFmrEF and HFpEF Management
SGLT2 inhibitors now have Class 1A recommendation for heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) based on 2023 ESC focused updates 2. This represents a major advance, as SGLT2i are now the only medication class with strong evidence across the entire ejection fraction spectrum.
Common Pitfalls to Avoid
Clinical Inertia and Delayed Initiation
Real-world data show alarming gaps: only 1-2% of HFrEF patients receive quadruple therapy, and mean time to SGLT2i initiation post-hospitalization is 88 days 3. This delay costs lives—initiate GDMT during hospitalization or immediately at discharge, not weeks later.
Premature Discontinuation
Discontinuation rates at 12 months are unacceptably high: ARNi 62%, MRA 57%, SGLT2i 55%, beta-blockers 51% 3. Proactive monitoring and patient education about temporary side effects versus long-term mortality benefits are essential.
Undertitration
Many patients remain on subtherapeutic doses. Uptitration should be aggressive but safe—the STRONG-HF trial validated rapid uptitration strategies with structured follow-up, demonstrating significant reductions in 180-day mortality and readmissions 4.
Monitoring and Titration Approach
After initiating low-dose therapy:
- Uptitrate every 1-2 weeks as tolerated based on blood pressure, heart rate, renal function, and potassium
- Target doses matter: Higher GDMT scores (reflecting both use and dose intensity) correlate with better outcomes 5
- Flexible sequencing: If one medication causes intolerance, continue uptitrating the others rather than abandoning the entire regimen
- Close follow-up: Structured monitoring within 1-2 weeks of discharge is critical for successful implementation 4
Device Therapy Integration
Once GDMT is optimized (or optimization attempted), reassess for device indications including cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) based on persistent LVEF ≤35%, QRS duration, and symptom burden 1.